Related Events

The stock price of Indiana-based Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.

The drug, vintafolide, received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency to treat a small group of ovarian cancer patients who have already tried other treatments.

Assuming that opinion is followed by the European Commission, Endocyte and its partner Merck & Co. Inc. would begin selling the drug and its companion imaging agent later this year.

The drug, which will be sold by Merck, has received the brand name of Vynfinit while the imaging agent will have the brand Folcepri, and will be sold by Endocyte.

Also, West Lafayette-based Endocyte announced that vintafolide proved effective at treating non-small cell lung cancer in a Phase 2 trial. Patients receiving vintafolide and traditional chemotherapy agents had a 25-percent reduction in the risk of death or of their cancer worsening, compared with patients receiving only chemotherapy.

The study confirms that Endocyte is “a platform technology company, along the same lines as” ImmunoGen Inc. and Seattle Genetics Inc., wrote RBC Capital Markets analysts Adnan Butt, in an e-mail to Bloomberg News. He added that Endocyte could be a candidate for a merger or acquisition “with an attractive product, pipeline and technology.”

The dual announcements, both released before the markets opened Friday, ignited investors’ interest. They bid up Endocyte shares as high $33.70 apiece, compared with Thursday’s closing price of $14.64.

Endocyte’s technology was first developed at Purdue University by chemist Philip Low. Since some cancer tumors have an abundance of “receptors” that bind easily with the vitamin folate, Low figured a powerful chemotherapy drug could be combined with a folate molecule, so it would target only cancerous cells and not healthy cells.

That allows vintafolide to be more deadly to cancer, without serious side effects, than patients can tolerate with traditional chemotherapy agents.

“We’ve studied vintafolide in two of the toughest-to-treat cancers and seen positive results and we view this as a continuing validation of the drug and the platform,” CEO Ron Ellis said on a conference call Friday.

The company could be a candidate for a merger or acquisition “with an attractive product, pipeline and technology,” said Butt, the analyst, who didn’t mention any potential suitors by name. The study confirms that Endocyte is “a platform-technology company, along the same lines as” ImmunoGen Inc. and Seattle Genetics Inc. he said.

ADVERTISEMENT

ReporterHealthcare, life sciences, education

Health Care & Life Sciences WeeklyIndustry e-newsletter writer

Wall's career as a journalist was set in fifth grade, when he took on an afternoon paper route for The Indianapolis News. He admits to being a terrible paperboy because instead of delivering the newspaper right away, he would sit and read it for hours. He may have lost some customers, but he never lost the bug for news. A lifelong resident of central Indiana, Wall grew up in Sheridan—the one spot in Hamilton County untouched by suburbia. After graduating from DePauw University in Greencastle, he joined The Indianapolis Star as a business reporting intern and refused to leave until he had a full-time job. Wall stayed there five years before joining IBJ in February 2007. Wall and his wife now live in Indianapolis with their two sons. When not at the office, the Walls spend time with their extended family and worship at Christ Church Reformed Presbyterian in Brownsburg.

all’s career as a journalist was set in fifth grade, when he took on an afternoon paper route for The Indianapolis News. He admits to being a terrible paperboy because instead of delivering the newspaper right away, he would sit and read it for hours. He may have lost some customers, but he never lost the bug for news. A lifelong resident of central Indiana, Wall grew up in Sheridan—the one spot in Hamilton County untouched by suburbia. After graduating from DePauw University in Greencastle, he joined The Indianapolis Star as a business reporting intern and refused to leave until he had a full-time job. Wall stayed there five years before joining IBJ in February 2007. Wall and his wife now live in Indianapolis with their two sons. When not at the office, the Walls spend time with their extended family and worship at Christ Church Reformed Presbyterian in Brownsburg

Multimedia

Videos

Nominations

Events

CTO of the Year Awards You've taken the time to nominate your top technology leaders, now it's time to find out who came out on top! Tickets are on sale now for IBJ & TechPoint's CTO of the Year August 23rd! Get your tickets today!.

Commercial Real Estate Power Breakfast Get the scoop on Indy’s commercial real estate scene at our Commercial Real Estate & Construction Power Breakfast on September 12th. Get your tickets today!.

Close

IBJ and our partners use technology such as cookies on our site to personalize content, provide social media features, and analyze our traffic. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Use.